



Express Mail Label No.: EV 019 436 092 US  
Date of Deposit: August 15, 2002

Attorney Docket No. VPI/00-130.08 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: D. Bebbington, et al.  
ASSIGNEE: Vertex Pharmaceuticals Incorporated  
SERIAL NUMBER: 10/722,374 EXAMINER: V. Balasubramanian  
FILING DATE: November 25, 2003 ART UNIT: 1614  
FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

March 18, 2004  
Cambridge, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the National Application;
- within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

**APPLICANTS:** Bebbington, et al.  
**U.S.S.N.:** 10/722,374

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-130-08 CON US.

Respectfully submitted,



Karoline Shair, Reg. No. 44,332  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6536  
Fax: (617) 444-6483



<p>Modified Form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>	<p><b>Application Number</b></p> <p><b>Filing Date</b></p> <p><b>First Named Inventor</b></p> <p><b>Group Art Unit</b></p> <p><b>Examiner Name</b></p> <p><b>Attorney Docket Number</b></p>	<p>November 25, 2003</p> <p>David Bebbington</p>
--	---	--

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
S							


FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1*	WO 00/21955	Zeneca Limited	20-Apr-2000	
	B2*	WO 00/39101	AstraZeneca UK Limited	06-Jul-2000	
	B3*	WO 02/18346	Pfizer Products Inc.	07-Mar-2002	

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/034,683, filed December 20, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

**Our Docket No.: VPI/00-130-08 CON US**



**Certificate Of Mailing Under 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On March 18, 2004.  
Date

1. Information Disclosure Statement (in duplicate);
2. PTO-1449 Form (in duplicate);
3. This Return Postcard Receipt.

Karen DiRocco  
Signature

Karen DiRocco  
Typed or printed name of person signing Certificate